Home / Business and Economy / Delivery Surge and Pharma Setback Shake Up Markets
Delivery Surge and Pharma Setback Shake Up Markets
15 Nov
Summary
- DoorDash stock jumps 6% on new Old Navy partnership
- Bristol-Myers Squibb ends heart drug trial, shares drop 4.1%
- Micron Technology named a "top pick" by Morgan Stanley
On Friday, November 14, 2025, the markets saw a mix of fortunes for major companies. Delivery giant DoorDash saw its stock surge 6% after announcing a partnership with clothing retailer Old Navy, marking a move beyond its core restaurant delivery business.
In contrast, pharmaceutical firm Bristol-Myers Squibb faced a setback as it ended a late-stage clinical trial of an experimental heart treatment called milvexian, which it was developing in collaboration with Johnson & Johnson. Shares of Bristol-Myers Squibb dropped 4.1% on the news.
Elsewhere, memory chip manufacturer Micron Technology received a boost, with Morgan Stanley naming it a "top pick" and raising its price target. Analysts cited strong demand for Micron's Double Data Rate 5 products, particularly related to the buildout of AI data centers.
Overall, the major U.S. equity indexes ended the session with mixed results, but posted gains for the week. With the federal government shutdown now over, attention has turned to the potential impact of delayed economic reports on the Federal Reserve's final interest-rate decision of 2025.
